Administration effects of single‑dose GnRH agonist for luteal support in females undertaking IVF/ICSI cycles: A meta‑analysis of randomized controlled trials

Song,Mengling; Liu,Chunlian; Hu,Rong; Wang,Feimiao; Huo,Zhenghao

doi:10.3892/etm.2019.8251

Administration effects of single‑dose GnRH agonist for luteal support in females undertaking IVF/ICSI cycles: A meta‑analysis of randomized controlled trials

Authors:
- Mengling Song
- Chunlian Liu
- Rong Hu
- Feimiao Wang
- Zhenghao Huo
View Affiliations

Affiliations: Department of Reproductive Medicine, General Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region 750004, P.R. China, Key Laboratory of Fertility Preservation and Maintenance of Ministry of Education, Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region 750004, P.R. China
Published online on: November 27, 2019 https://doi.org/10.3892/etm.2019.8251
Pages: 786-796

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present meta‑analysis was to evaluate the effects of the addition of single‑dose gonadotropin‑releasing hormone agonist (GnRHa) for luteal support on pregnancy outcomes in females partaking in in vitro fertilization or intracytoplasmic sperm injection cycles. In total, the studies were hand‑searched from six electronic databases to compare the pregnancy outcomes between single‑dose GnRHa administered as luteal phase support (GnRHa group) and regular luteal support (control group). In the GnRHa group, single‑dose GnRH agonist were administered at 5/6 days after IVF/ICSI procedures. In the control group, single‑dose GnRH agonist was not added during luteal phase support. Only randomized controlled trials were included. Sensitivity analysis was performed using Revman 5.3 software; the high heterogeneity identified in the present analysis was primarily caused by one study included. Following exclusion of this particular study, the meta‑analysis results indicated significantly higher rates of ongoing pregnancy or live birth per transfer (P=0.002), clinical pregnancy per transfer (CPR; P=0.001) and multiple pregnancy per pregnancy (P=0.020) in the GnRHa group compared with those in the control group. Meta‑analysis of a subgroup of trials with long‑acting GnRH‑a ovarian treatment protocols indicated that the rate of ongoing pregnancy or live birth (P=0.080), CPR (P=0.090) and multiple pregnancy per pregnancy (P=0.140) were not significantly different between the two groups. However, the results from trials that had used a multi‑dose GnRH antagonist ovarian treatment protocol indicated a significantly higher ongoing pregnancy or live birth rate per transfer (P=0.010), CPR per transfer (P<0.0001) and multiple pregnancy rate per pregnancy (P=0.003) compared with those in the control group. The present results suggested that administration of single‑dose GnRH agonist in the luteal phase may be an ideal choice for patients undergoing IVF/ICSI therapy.

View Figures

View References

1	Tavaniotou A, Albano C, Smitz J and Devroey P: Impact ofovarian stimulation on corpus luteum function and embryonicimplantation. J Reprod Immunol. 55:123–130. 2002. View Article : Google Scholar : PubMed/NCBI
2	Pritts EA and Atwood AK: Luteal phase support in infertilitytreatment: A meta-analysis of the randomized trials. Hum Reprod. 17:2287–2299. 2002. View Article : Google Scholar : PubMed/NCBI
3	van der Linden M, Buckingham K, Farquhar C, Kremer JA and Metwally M: Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. CD0091542015.PubMed/NCBI
4	Fatemi HM: The luteal phase after 3 decades of IVF: What do we know? Reprod Biomed Online. 19 (Suppl 4):S43312009. View Article : Google Scholar
5	Devroey P, Bourgain C, Macklon NS and Fauser BC: Reproductive biology and IVF: Ovarian stimulationand endometrial receptivity. Trends Endocrinol Metab. 15:84–90. 2004. View Article : Google Scholar : PubMed/NCBI
6	Gizzo S, Andrisani A, Esposito F, Noventa M, Di Gangi S, Angioni S, Litta P, Gangemi M and Nardelli GB: Which luteal phase support is better for each IVF stimulation protocol to achieve the highest pregnancy rate? A superiority randomized clinical trial. Gynecol Endocrinol. 30:902–908. 2014. View Article : Google Scholar : PubMed/NCBI
7	Fujii S, Sato S, Fukui A, Kimura H, Kasai G and Saito Y: Continuous administration of gonadotrophin-releasing hormone agonist during the luteal phase in IVF. Hum Reprod. 16:1671–1675. 2001. View Article : Google Scholar : PubMed/NCBI
8	Tesarik J, Hazout A and Mendoza C: Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Hum Reprod. 19:1176–1180. 2004. View Article : Google Scholar : PubMed/NCBI
9	Casan EM, Raga F and Polan ML: GnRH mRNA and protein expression in human preimplantation embryos. Mol Hum Reprod. 5:234–239. 1999. View Article : Google Scholar : PubMed/NCBI
10	Nam DH, Lee SH, Kim HS, Lee GS, Jeong YW, Kim S, Kim JH, Kang SK, Lee BC and Hwang WS: The role of gonadotropin-releasing hormone (GnRH) and its receptor in development of porcine preimplantation embryos derived from in vitro fertilization. Theriogenology. 63:190–201. 2005. View Article : Google Scholar : PubMed/NCBI
11	Raga F, Casan EM, Kruessel J, Wen Y, Bonilla-Musoles F and Polan ML: The role of gonadotropin- releasing hormone in murine preimplantation embryonic development. Endocrinology. 140:3705–3712. 1999. View Article : Google Scholar : PubMed/NCBI
12	Kyrou D, Kolibianakis EM, Fatemi HM, Tarlatzi TB, Devroey P and Tarlatzis BC: Increased live birth rates with GnRH agonist addition for luteal support in ICSI/IVF cycles: A systematic review and meta-analysis. Hum Reprod Update. 17:734–740. 2011. View Article : Google Scholar : PubMed/NCBI
13	Oliveira JB, Baruffi R, Petersen CG, Mauri AL, Cavagna M and Franco JG Jr: Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: A meta-analysis. Reprod Biol Endocrinol. 8:1072010. View Article : Google Scholar : PubMed/NCBI
14	Yu LP, Liu N and Liu Y: Effect of luteal-phase gonadotropin-releasing hormone agonist administration on pregnancy outcome in IVF/ICSI cycles: A systematic review and Meta-analysis. Zhonghua Fu Chan Ke Za Zhi. 51:850–858. 2016.(In Chinese). PubMed/NCBI
15	Zhou W, Zhuang Y, Pan Y and Xia F: Effects and safety of GnRH-a as a luteal support in women undertaking assisted reproductive technology procedures: Follow-up results for pregnancy, delivery, and neonates. Arch Gynecol Obstet. 295:1269–1275. 2017. View Article : Google Scholar : PubMed/NCBI
16	Martins WP, Ferriani RA, Navarro PA and Nastri CO: GnRH agonist during luteal phase for women undergoing assisted reproductive techniques: Systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol. 47:144–151. 2016. View Article : Google Scholar : PubMed/NCBI
17	Gordon A, Raynes-Greenow C, McGeechan K, Morris J and Jeffery H: Risk factors for antepartum stillbirth and the influence of maternal age in New South Wales Australia: A population based study. BMC Pregnancy Childbirth. 13:122013. View Article : Google Scholar : PubMed/NCBI
18	Reddy UM, Laughon SK, Sun L, Troendle J, Willinger M and Zhang J: Prepregnancy risk factors for antepartum stillbirth in the United States. Obstet Gynecol. 116:1119–1126. 2010. View Article : Google Scholar : PubMed/NCBI
19	Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N and Mendoza C: Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod. 21:2572–2579. 2006. View Article : Google Scholar : PubMed/NCBI
20	Ata B, Yakin K, Balaban B and Urman B: GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the long GnRH agonist protocol: A randomized, controlled double blind study. Hum Reprod. 23:668–673. 2008. View Article : Google Scholar : PubMed/NCBI
21	Isik AZ, Caglar GS, Sozen E, Akarsu C, Tuncay G, Ozbicer T and Vicdan K: Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: A prospective randomized study. Reprod Biomed Online. 19:472–477. 2009. View Article : Google Scholar : PubMed/NCBI
22	Razieh DF, Maryam AR and Nasim T: Beneficial effect of luteal-phase gonadotropin-releasing hormone agonist administration on implantation rate after intracytoplasmic sperm injection. Taiwan J Obstet Gynecol. 48:245–248. 2009. View Article : Google Scholar : PubMed/NCBI
23	Ata B and Urman B: Single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles: Is the effect dependent on the type of GnRH analogue used for pituitary suppression? Reprod Biomed Online. 20:165–166. 2010. View Article : Google Scholar : PubMed/NCBI
24	Yildiz GA, Şükür YE, Ateş C and Aytaç R: The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 182:66–70. 2014. View Article : Google Scholar : PubMed/NCBI
25	Zafardoust S, Jeddi-Tehrani M, Akhondi MM, Sadeghi MR, Kamali K, Mokhtar S, Badehnoosh B, Arjmand-Teymouri F, Fatemi F and Mohammadzadeh A: Effect of administration of single dose GnRH agonist in luteal phase on outcome of ICSI-ET cycles in women with previous history of IVF/ICSI failure: A randomized controlled trial. J Reprod Infertili. 16:116–120. 2015.
26	Benmachiche A, Benbouhedja S, Zoghmar A, Boularak A and Humaidan P: Impact of mid-luteal phase GnRH agonist administration on reproductive outcomes in GnRH agonist-triggered cycles: A randomized controlled trial. Front Endocrinol (Lausanne). 8:1242017. View Article : Google Scholar : PubMed/NCBI
27	Wilshire GB, Emmi AM, Gagliardi CC and Weiss G: Gonadotropin-releasing hormone agonist administration in early human pregnancy is associated with normal outcomes. Fertil Steril. 60:980–983. 1993. View Article : Google Scholar : PubMed/NCBI
28	Pirard C, Loumaye E, Laurent P and Wyns C: Contribution to more patient-friendly ART treatment: Efficacy of continuous low-dose GnRH agonist as the only luteal support-results of a prospective, randomized, comparative study. Int J Endocrinol. 2015:7275692015. View Article : Google Scholar : PubMed/NCBI
29	Aboulghar MA, Marie H, Amin YM, Aboulghar MM, Nasr A, Serour GI and Mansour RT: GnRH agonist plus vaginal progesterone for luteal phase support in ICSI cycles: A randomized study. Reprod Biomed Online. 30:52–56. 2015. View Article : Google Scholar : PubMed/NCBI
30	Chillik CF, Itskovitz J, Hahn DW, McGuire GL, Danforth DR and Hodgen GD: Characterizing pituitary response to a gonadotropin-releasing hormone (GnRH) antagonist in monkeys: Tonic follicle-stimulating hormone/luteinizing hormone secretion versus acute GnRH challenge tests before, during, and after treatment. Fertil Steril. 48:480–485. 1987. View Article : Google Scholar : PubMed/NCBI
31	Gordon K, Williams RF, Danforth DR and Hodgen GD: A novel regimen of gonadotropin-releasing hormone (GnRH) antagonist plus pulsatile GnRH: Controlled restoration of gonadotropin secretion and ovulation induction. Fertil Steril. 54:1140–1145. 1990. View Article : Google Scholar : PubMed/NCBI
32	Felberbaum RE, Reissmann T, Küpker W, Bauera O, al Hasania S, Diedrich C and Diedricha K: Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility. Eur J Obstet Gynecol Reprod Biol. 61:151–155. 1995. View Article : Google Scholar : PubMed/NCBI
33	Iwashita M, Kudo Y, Shinozaki Y and Takeda Y: Gonadotropin-releasing hormone increases serum human chorionic gonadotropin in pregnant women. Endocr J. 40:539–544. 1993. View Article : Google Scholar : PubMed/NCBI
34	Lin LS, Roberts VJ and Yen SS: Expression of human gonadotropin-releasing hormone receptor gene in the placenta and its functional relationship to human chorionic gonadotropin secretion. J Clin Endocrinol Metab. 80:580–585. 1995. View Article : Google Scholar : PubMed/NCBI